( OTC-BB:SRNE,OTC-PINK:SRNE )

News from Sorrento Therapeutics, Inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 14, 2014, 23:57 ET Sorrento Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...


May 14, 2014, 16:40 ET Sorrento Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Sorrento Therapeutics, Inc. (Nasdaq: SRNE) ("Sorrento" or the "Company"), a late-stage clinical oncology company developing new treatments for...


May 13, 2014, 07:30 ET Sorrento Announces Transfer of Orphan Drug Designation Sponsorship for Intrathecal Resiniferatoxin from NIH

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...


Apr 07, 2014, 15:58 ET Sorrento appoints Ian Walters as Senior Vice President of Translational Medicine and Corporate Development

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...


Mar 31, 2014, 21:31 ET Sorrento Announces First Patient Dosed in Registration Trial to Evaluate Bioequivalence Between Cynviloq and Abraxane

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...


Mar 25, 2014, 07:47 ET Sorrento Therapeutics Forms Subsidiary Ark Animal Therapeutics to Develop Animal Health Applications

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...


Mar 06, 2014, 06:00 ET Sorrento Therapeutics to Present at ROTH Capital Partners 26th Annual Growth Stock Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...


Mar 06, 2014, 05:50 ET Sorrento Therapeutics Announces Three Presentations and a Satellite Symposium on Cynviloq™ at the 31st Annual Miami Breast Cancer Conference

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated...


Feb 11, 2014, 08:00 ET Sorrento Therapeutics Announces Two Presentations on Cynviloq™ at the Beaujon International Conference on "Cutting Edge in Liver and Pancreatic Tumors"

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...


Feb 10, 2014, 16:00 ET Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq™ to Include Australia, Canada and Mexico

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and...


Feb 03, 2014, 06:00 ET Sorrento Therapeutics Welcomes Daniel Levitt as a Director to its Board

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and associated...


Jan 10, 2014, 12:50 ET Sorrento Therapeutics to Present at the Biotech Showcase 2014 and the 7th Annual OneMed Forum SF2014 in San Francisco

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com) announced today that Dr. Henry Ji, President and Chief Executive...


Jan 09, 2014, 09:00 ET Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and...


Jan 08, 2014, 09:00 ET Sorrento Therapeutics Appoints Amar Singh as Executive Vice President and Chief Business Officer

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento; www.sorrentotherapeutics.com), a late-stage clinical oncology company developing new...


Dec 19, 2013, 19:10 ET Sorrento Therapeutics Completes Acquisition of Concortis Biosystems

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has completed its acquisition of Concortis Biosystems, Corp.,...


Nov 14, 2013, 07:00 ET Sorrento Enters into Definitive Agreement to Acquire Antibody Drug Conjugation Technology

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today the entry into a definitive agreement to acquire San Diego-based Concortis...


Nov 12, 2013, 08:00 ET Sorrento Therapeutics Adopts Stockholder Rights Plan

Sorrento Therapeutics,  Inc. (NASDAQ: SRNE) announced that its Board of Directors adopted a stockholder rights plan (the "Rights Plan" or...


Nov 05, 2013, 08:00 ET Sorrento Therapeutics Enters into Antibody and Vaccine Development Alliance for the Prevention and Treatment of Obesity

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an antibody and vaccine development...


Oct 30, 2013, 14:07 ET Sorrento Therapeutics Announces Closing of Public Offering of Common Stock

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) today announced the closing of its previously announced underwritten public offering.  The...


Oct 25, 2013, 16:10 ET Sorrento Therapeutics Announces Full Exercise of Over-Allotment Option

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the  full exercise of the over-allotment option granted to the underwriters to...